Turning cold tumors hot: from molecular mechanisms to clinical applications

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works

Oncology meets immunology: the cancer-immunity cycle.

Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · see citing works

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · see citing works

The Immune Landscape of Cancer

Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870 · see citing works

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671 · see citing works

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400 · see citing works

Elements of cancer immunity and the cancer–immune set point

Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · see citing works

The future of immune checkpoint therapy

Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · see citing works

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients

Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · see citing works

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071 · see citing works

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788 · see citing works

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,414 · see citing works

Pembrolizumab for Early Triple-Negative Breast Cancer

Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270 · see citing works

Functional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid

Colegio, O. R., Chu, N.-Q., Szabo, A. L., Chu, T., Rhebergen, A. M., Jairam, V., Cyrus, N., Brokowski, C. E., Eisenbarth, S. C., Phillips, G. M., et al. (2014) · Nature · doi:10.1038/nature13490 · Cited by 3,046 · see citing works

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830 · see citing works

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552 · see citing works

The human tumor microbiome is composed of tumor type–specific intracellular bacteria

Nejman, D., Livyatan, I., Fuks, G., Gavert, N., Zwang, Y., Geller, L. T., Rotter-Maskowitz, A., Weiser, R., Mallel, G., Gigi, E., et al. (2020) · Science · doi:10.1126/science.aay9189 · Cited by 2,464 · see citing works

Tertiary lymphoid structures improve immunotherapy and survival in melanoma

Cabrita, R., Lauss, M., Sanna, A., Donia, M., Skaarup Larsen, M., Mitra, S., Johansson, I., Phung, B., Harbst, K., Vallon-Christersson, J., et al. (2020) · Nature · doi:10.1038/s41586-019-1914-8 · Cited by 2,374 · see citing works

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301 · see citing works

Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy

Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.49 · Cited by 2,217 · see citing works

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099 · see citing works

Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

Miller, B. C., Sen, D. R., Al Abosy, R., Bi, K., Virkud, Y. V., LaFleur, M. W., Yates, K. B., Lako, A., Felt, K., Naik, G. S., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0312-6 · Cited by 2,087 · see citing works

The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment

Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008 · see citing works

B cells are associated with survival and immunotherapy response in sarcoma

Petitprez, F., de Reyniès, A., Keung, E. Z., Chen, T. W.-W., Sun, C.-M., Calderaro, J., Jeng, Y.-M., Hsiao, L.-P., Lacroix, L., Bougoüin, A., et al. (2020) · Nature · doi:10.1038/s41586-019-1906-8 · Cited by 1,942 · see citing works

Turning foes to friends: targeting cancer-associated fibroblasts

Chen, X., & Song, E. (2018) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0004-1 · Cited by 1,884 · see citing works

Tertiary lymphoid structures in the era of cancer immunotherapy

Sautès-Fridman, C., Petitprez, F., Calderaro, J., & Fridman, W. H. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0144-6 · Cited by 1,884 · see citing works

NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control

Böttcher, J. P., Bonavita, E., Chakravarty, P., Blees, H., Cabeza-Cabrerizo, M., Sammicheli, S., Rogers, N. C., Sahai, E., Zelenay, S., & Reis e Sousa, C. (2018) · Cell · doi:10.1016/j.cell.2018.01.004 · Cited by 1,857 · see citing works

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851 · see citing works

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Choueiri, T. K., Powles, T., Burotto, M., Escudier, B., Bourlon, M. T., Zurawski, B., Oyervides Juárez, V. M., Hsieh, J. J., Basso, U., Shah, A. Y., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2026982 · Cited by 1,791 · see citing works

Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients

Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., et al. (2021) · Science · doi:10.1126/science.abb5920 · Cited by 1,757 · see citing works

Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults

Bhaskaran, K., Douglas, I., Forbes, H., dos-Santos-Silva, I., Leon, D. A., & Smeeth, L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60892-8 · Cited by 1,707 · see citing works

Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy

Siddiqui, I., Schaeuble, K., Chennupati, V., Fuertes Marraco, S. A., Calderon-Copete, S., Pais Ferreira, D., Carmona, S. J., Scarpellino, L., Gfeller, D., Pradervand, S., et al. (2019) · Immunity · doi:10.1016/j.immuni.2018.12.021 · Cited by 1,679 · see citing works

Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes

Riquelme, E., Zhang, Y., Zhang, L., Montiel, M., Zoltan, M., Dong, W., Quesada, P., Sahin, I., Chandra, V., San Lucas, A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.07.008 · Cited by 1,577 · see citing works

Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy

Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539 · see citing works

Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer

Kather, J. N., Pearson, A. T., Halama, N., Jäger, D., Krause, J., Loosen, S. H., Marx, A., Boor, P., Tacke, F., Neumann, U. P., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0462-y · Cited by 1,458 · see citing works

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., Mathewson, N. D., Li, S., Oliveira, G., Giobbie-Hurder, A., Felt, K., Gjini, E., et al. (2019) · Nature · doi:10.1038/s41586-018-0792-9 · Cited by 1,432 · see citing works

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

Jerby-Arnon, L., Shah, P., Cuoco, M. S., Rodman, C., Su, M.-J., Melms, J. C., Leeson, R., Kanodia, A., Mei, S., Lin, J.-R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.006 · Cited by 1,429 · see citing works

Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy

Mager, L. F., Burkhard, R., Pett, N., Cooke, N. C. A., Brown, K., Ramay, H., Paik, S., Stagg, J., Groves, R. A., Gallo, M., et al. (2020) · Science · doi:10.1126/science.abc3421 · Cited by 1,407 · see citing works

Pan-cancer single-cell landscape of tumor-infiltrating T cells

Zheng, L., Qin, S., Si, W., Wang, A., Xing, B., Gao, R., Ren, X., Wang, L., Wu, X., Zhang, J., et al. (2021) · Science · doi:10.1126/science.abe6474 · Cited by 1,402 · see citing works

Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates

Simoni, Y., Becht, E., Fehlings, M., Loh, C. Y., Koo, S.-L., Teng, K. W. W., Yeong, J. P. S., Nahar, R., Zhang, T., Kared, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0130-2 · Cited by 1,370 · see citing works

Metabolic support of tumour-infiltrating regulatory T cells by lactic acid

Watson, M. J., Vignali, P., Mullett, S. J., Overacre-Delgoffe, A. E., Peralta, R. M., Grebinoski, S., Menk, A. V., Rittenhouse, N., DePeaux, K., Whetstone, R. D., et al. (2021) · Nature · doi:10.1038/s41586-020-03045-2 · Cited by 1,280 · see citing works

Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I

Yamamoto, K., Venida, A., Yano, J., Biancur, D. E., Kakiuchi, M., Gupta, S., Sohn, A. S. W., Mukhopadhyay, S., Lin, E. Y., Parker, S. J., et al. (2020) · Nature · doi:10.1038/s41586-020-2229-5 · Cited by 1,240 · see citing works

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study

Sun, R., Limkin, E. J., Vakalopoulou, M., Dercle, L., Champiat, S., Han, S. R., Verlingue, L., Brandao, D., Lancia, A., Ammari, S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30413-3 · Cited by 1,236 · see citing works

CD10+GPR77+ Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness

Su, S., Chen, J., Yao, H., Liu, J., Yu, S., Lao, L., Wang, M., Luo, M., Xing, Y., Chen, F., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.009 · Cited by 1,230 · see citing works

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells

André, P., Denis, C., Soulas, C., Bourbon, C., Lopez, J., Arnoux, T., Bléry, M., Bonnafous, C., Gauthier, L., Morel, A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.014 · Cited by 1,229 · see citing works

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy

Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201 · see citing works

The microbiome, cancer, and cancer therapy

Helmink, B. A., Khan, M. A. W., Hermann, A., Gopalakrishnan, V., & Wargo, J. A. (2019) · Nature Medicine · doi:10.1038/s41591-019-0377-7 · Cited by 1,200 · see citing works

A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity

Jacob, F., Salinas, R. D., Zhang, D. Y., Nguyen, P. T. T., Schnoll, J. G., Wong, S. Z. H., Thokala, R., Sheikh, S., Saxena, D., Prokop, S., et al. (2020) · Cell · doi:10.1016/j.cell.2019.11.036 · Cited by 1,149 · see citing works

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142 · see citing works

Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity

Zhang, Q., Bi, J., Zheng, X., Chen, Y., Wang, H., Wu, W., Wang, Z., Wu, Q., Peng, H. C., Wei, H., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0132-0 · Cited by 1,122 · see citing works

PI3Kγ is a molecular switch that controls immune suppression

Kaneda, M. M., Messer, K., Ralainirina, N., Li, H., Leem, C. J., Gorjestani, S., Woo, G., Nguyen, A. V., Figueiredo, C. C., Foubert, P., et al. (2016) · Nature · doi:10.1038/nature19834 · Cited by 1,118 · see citing works

Multimodal Analysis of Composition and Spatial Architecture in Human Squamous Cell Carcinoma

Ji, A. L., Rubin, A. J., Thrane, K., Jiang, S., Reynolds, D. L., Meyers, R. M., Guo, M. G., George, B. M., Mollbrink, A., Bergenstråhle, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.039 · Cited by 1,117 · see citing works

Cold Tumors: A Therapeutic Challenge for Immunotherapy

Bonaventura, P., Shekarian, T., Alcazer, V., Valladeau‐Guilemond, J., Valsesia‐Wittmann, S., Amigorena, S., Caux, C., & Depil, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00168 · Cited by 1,102 · see citing works

Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma

Li, H., van der Leun, A. M., Yofe, I., Lubling, Y., Gelbard-Solodkin, D., van Akkooi, A. C. J., van den Braber, M., Rozeman, E. A., Haanen, J. B. A. G., Blank, C. U., et al. (2019) · Cell · doi:10.1016/j.cell.2018.11.043 · Cited by 1,101 · see citing works

Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms

Beltra, J., Manne, S., Abdel-Hakeem, M. S., Kurachi, M., Giles, J. R., Chen, Z., Casella, V., Ngiow, S. F., Khan, O., Huang, Y., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.014 · Cited by 1,091 · see citing works

Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer.

Arbour, K. C., Mezquita, L., Long, N., Rizvi, H., Auclin, E., Ni, A., Martínez-Bernal, G., Ferrara, R., Lai, W. V., Hendriks, L. E. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.0006 · Cited by 1,071 · see citing works

ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach

Luchini, C., Bibeau, F., Ligtenberg, M. J. L., Singh, N., Nottegar, A., Bosse, T., Miller, R. E., Riaz, N., Douillard, J.-Y., André, F., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz116 · Cited by 1,044 · see citing works

Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment

Ma, X., Bi, E., Lu, Y., Su, P., Huang, C., Liu, L., Wang, Q., Yang, M., Kalady, M. F., Qian, J., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.04.002 · Cited by 1,033 · see citing works

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

McGrail, D. J., Pilié, P. G., Rashid, N. U., Voorwerk, L., Slagter, M., Kok, M., Jonasch, E. W., Khasraw, M., Heimberger, A. B., Lim, B., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.006 · Cited by 1,030 · see citing works

CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability

Ma, X., Xiao, L., Liu, L., Ye, L., Pan, S., Bi, E., Wang, Q., Yang, M., Qian, J., & Yi, Q. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.02.015 · Cited by 1,022 · see citing works

A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments

Barry, K. C., Hsu, J., Broz, M. L., Cueto, F. J., Binnewies, M., Combes, A. J., Nelson, A. E., Loo, K., Kumar, R., Rosenblum, M. D., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0085-8 · Cited by 1,021 · see citing works

Tumor Endothelium FasL Establishes a Selective Immune Barrier Promoting Tolerance in Tumors

Motz, G. T., Santoro, S. P., Wang, L.-P., Garrabrant, T., Lastra, R., Hagemann, I., Lal, P., Feldman, M., Benencia, F., & Coukos, G. (2014) · Nature Medicine · doi:10.1038/nm.3541 · Cited by 980 · see citing works

Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells

Han, D., Liu, J., Chen, C., Dong, L., Liu, Y., Chang, R., Huang, X., Liu, Y., Wang, J., Dougherty, U., et al. (2019) · Nature · doi:10.1038/s41586-019-0916-x · Cited by 955 · see citing works

Phagocytosis checkpoints as new targets for cancer immunotherapy

Feng, M., Jiang, W., Kim, B. Y. S., Zhang, C. C., Fu, Y., & Weissman, I. L. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0183-z · Cited by 914 · see citing works

Design of amidobenzimidazole STING receptor agonists with systemic activity

Ramanjulu, J. M., Pesiridis, G. S., Yang, J., Concha, N., Singhaus, R., Zhang, S.-Y., Tran, J.-L., Moore, P., Lehmann, S., Eberl, H. C., et al. (2018) · Nature · doi:10.1038/s41586-018-0705-y · Cited by 912 · see citing works

β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma

Ruiz de Galarreta, M., Bresnahan, E., Molina-Sánchez, P., Lindblad, K. E., Maier, B., Sia, D., Puigvehi, M., Miguela, V., Casanova-Acebes, M., Dhainaut, M., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0074 · Cited by 912 · see citing works

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

Derosa, L., Hellmann, M. D., Spaziano, M., Halpenny, D., Fidelle, M., Rizvi, H., Long, N., Plodkowski, A. J., Arbour, K. C., Chaft, J. E., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy103 · Cited by 908 · see citing works

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

Zhao, J., Chen, A. X., Gartrell, R. D., Silverman, A. M., Aparicio, L., Chu, T., Bordbar, D., Shan, D., Samanamud, J., Mahajan, A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0349-y · Cited by 903 · see citing works

TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection

Alfei, F., Kanev, K., Hofmann, M., Wu, M., Ghoneim, H. E., Roelli, P., Utzschneider, D. T., von Hoesslin, M., Cullen, J. G., Fan, Y., et al. (2019) · Nature · doi:10.1038/s41586-019-1326-9 · Cited by 900 · see citing works

Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition

Litchfield, K., Reading, J. L., Puttick, C., Thakkar, K., Abbosh, C., Bentham, R., Watkins, T. B. K., Rosenthal, R., Biswas, D., Rowan, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.002 · Cited by 893 · see citing works

Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients

Kahles, A., Lehmann, K.-V., Toussaint, N. C., Hüser, M., Stark, S. G., Sachsenberg, T. T., Stegle, O., Kohlbacher, O., Sander, C., Johnson, R., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.001 · Cited by 891 · see citing works

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

Blank, C. U., Rozeman, E. A., Fanchi, L. F., Sikorska, K., van de Wiel, B., Kvistborg, P., Krijgsman, O., van den Braber, M., Philips, D., Broeks, A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0198-0 · Cited by 880 · see citing works

Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors

Dangaj, D., Bruand, M., Grimm, A. J., Ronet, C., Barras, D., Duttagupta, P. A., Lanitis, E., Duraiswamy, J., Tanyi, J. L., Benencia, F., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.004 · Cited by 875 · see citing works

Management of toxicities of immune checkpoint inhibitors

Spain, L., Diem, S., & Larkin, J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.001 · Cited by 854 · see citing works

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Amaria, R. N., Reddy, S. M., Tawbi, H. A., Davies, M. A., Ross, M. I., Glitza, I. C., Cormier, J. N., Lewis, C., Hwu, W.-J., Hanna, E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0197-1 · Cited by 835 · see citing works

Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment

Peranzoni, E., Lemoine, J., Vimeux, L., Feuillet, V., Barrin, S., Kantari-Mimoun, C., Bercovici, N., Guérin, M., Biton, J., Ouakrim, H., et al. (2018) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1720948115 · Cited by 817 · see citing works

Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade

Hsu, J., Hodgins, J. J., Marathe, M., Nicolai, C. J., Bourgeois-Daigneault, M.-C., Trevino, T. N., Azimi, C. S., Scheer, A. K., Randolph, H. E., Thompson, T. W., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99317 · Cited by 817 · see citing works

Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors

Xu, S., Chaudhary, O., Rodríguez-Morales, P., Sun, X., Chen, D., Zappasodi, R., Xu, Z. Z., Pinto, A. F. M., Williams, A. E., Schulze, I., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.05.003 · Cited by 815 · see citing works

TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8 ⁺ T cell exhaustion

Seo, H., Chen, J., González-Avalos, E., Samaniego-Castruita, D., Das, A., Wang, Y. H., López-Moyado, I. F., Georges, R. O., Zhang, W., Onodera, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1905675116 · Cited by 808 · see citing works

A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer

Wagner, J., Rapsomaniki, M., Chevrier, S., Anzeneder, T., Langwieder, C., Dykgers, A., Rees, M., Ramaswamy, A., Muenst, S. E., Soysal, S. D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.03.005 · Cited by 784 · see citing works

Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity

Ringel, A. E., Drijvers, J. M., Baker, G. J., Catozzi, A., García-Cañaveras, J. C., Gassaway, B. M., Miller, B. C., Juneja, V. R., Nguyen, T. H., Joshi, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.11.009 · Cited by 780 · see citing works

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0915 · Cited by 770 · see citing works

Peripheral T cell expansion predicts tumour infiltration and clinical response

Wu, T. D., Madireddi, S., de Almeida, P. E., Banchereau, R., Chen, Y.-J. J., Chitre, A. S., Chiang, E. Y., Iftikhar, H., O’Gorman, W. E., Au-Yeung, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2056-8 · Cited by 770 · see citing works

Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study

Necchi, A., Anichini, A., Raggi, D., Briganti, A., Massa, S., Lucianò, R., Colecchia, M., Giannatempo, P., Mortarini, R., Bianchi, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.01148 · Cited by 741 · see citing works

Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy

Li, J., Byrne, K. T., Yan, F., Yamazoe, T., Chen, Z., Baslan, T., Richman, L. P., Lin, J., Sun, Y. H., Rech, A. J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.06.006 · Cited by 738 · see citing works

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

Krieg, C., Nowicka, M., Guglietta, S., Schindler, S., Hartmann, F. J., Weber, L. M., Dummer, R., Robinson, M. D., Levesque, M. P., & Becher, B. (2018) · Nature Medicine · doi:10.1038/nm.4466 · Cited by 735 · see citing works

Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8+ T cell immunity

He, Y., Fu, L., Li, Y., Wang, W., Gong, M., Zhang, J., Dong, X., Huang, J., Wang, Q., Mackay, C. R., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.03.002 · Cited by 729 · see citing works

An intra-tumoral niche maintains and differentiates stem-like CD8 T cells

Jansen, C. S., Prokhnevska, N., Master, V., Sanda, M., Carlisle, J., Bilen, M., Cardenas, M., Wilkinson, S., Lake, R., Sowalsky, A., et al. (2019) · Nature · doi:10.1038/s41586-019-1836-5 · Cited by 724 · see citing works

WNT/β-catenin pathway activation correlates with immune exclusion across human cancers

Luke, J. J., Bao, R., Sweis, R. F., Spranger, S., & Gajewski, T. F. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1942 · Cited by 722 · see citing works

The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes

Dammeijer, F. F., van Gulijk, M., Mulder, E. E. A. P., Lukkes, M. M., Klaase, L., van den Bosch, T. P. P., van Nimwegen, M., Lau, S. P., Latupeirissa, K., Schetters, S. T. T., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.09.001 · Cited by 701 · see citing works

An orally available non-nucleotide STING agonist with antitumor activity

Pan, B.-S., Perera, S. A., Piesvaux, J. A., Presland, J. P., Schroeder, G. K., Cumming, J. N., Trotter, B. W., Altman, M. D., Buevich, A. V., Cash, B., et al. (2020) · Science · doi:10.1126/science.aba6098 · Cited by 694 · see citing works

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

Zhao, P., Li, L., Jiang, X., & Li, Q. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0738-1 · Cited by 682 · see citing works

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma

Huang, A. C. C., Orlowski, R. J., Xu, X., Mick, R., George, S. M., Yan, P., Manne, S., Kraya, A., Wubbenhorst, B. S., Dorfman, L. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0357-y · Cited by 680 · see citing works

CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors

Wang, H., Franco, F., Tsui, Y.-C., Xie, X., Trefny, M. P., Zappasodi, R., Mohmood, S. R., Fernández-García, J., Tsai, C.-H., Schulze, I., et al. (2020) · Nature Immunology · doi:10.1038/s41590-019-0589-5 · Cited by 680 · see citing works

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

McQuade, J. L., Daniel, C. R., Hess, K. R., Mak, C., Wang, D. Y., Rai, R. R., Park, J. J., Haydu, L. E., Spencer, C., Wongchenko, M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30078-0 · Cited by 664 · see citing works

An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer

Burr, M. L., Sparbier, C. E., Chan, K. L., Chan, Y.-C., Kersbergen, A. J., Lam, E. Y. N., Azidis-Yates, E., Vassiliadis, D., Bell, C. C., Gilan, O., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.008 · Cited by 656 · see citing works

Pan-cancer computational histopathology reveals mutations, tumor composition and prognosis

Fu, Y., Jung, A. W., Viñas, R., González, S., Vöhringer, H. S., Shmatko, A., Yates, L. R., Jimenez‐Liñan, M., Moore, L., & Gerstung, M. (2020) · Nature Cancer · doi:10.1038/s43018-020-0085-8 · Cited by 636 · see citing works

Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer

Latham, A. J., Srinivasan, P., Kemel, Y. M., Shia, J., Bandlamudi, C., Mandelker, D. L., Middha, S., Hechtman, J. F., Zehir, A., Dubard-Gault, M. E., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00283 · Cited by 618 · see citing works

Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade

Lu, S., Stein, J. E., Rimm, D. L., Wang, D. W., Bell, M. A., Johnson, D. B., Sosman, J. A., Schalper, K. A., Anders, R. A., Wang, H., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1549 · Cited by 618 · see citing works

KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer

Liao, W., Overman, M. J., Boutin, A. T., Shang, X., Zhao, D., Dey, P., Li, J., Wang, G., Lan, Z., Li, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.008 · Cited by 617 · see citing works

Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment

Lam, K. C., Araya, R. E., Huang, A., Chen, Q., Di Modica, M., Rodrigues, R. R., Lopès, A., Johnson, S. B., Schwarz, B., Bohrnsen, E., et al. (2021) · Cell · doi:10.1016/j.cell.2021.09.019 · Cited by 604 · see citing works

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma

Rodig, S. J., Gusenleitner, D., Jackson, D. G., Gjini, E., Giobbie-Hurder, A., Jin, C., Chang, H., Lovitch, S. B., Horak, C., Weber, J. S., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar3342 · Cited by 579 · see citing works

Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers

Scheper, W., Kelderman, S., Fanchi, L. F., Linnemann, C., Bendle, G. M., de Rooij, M. A. J., Hirt, C., Mezzadra, R., Slagter, M., Dijkstra, K. K., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0266-5 · Cited by 568 · see citing works

Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials

Theelen, W. S. M. E., Chen, D., Verma, V., Hobbs, B. P., Peulen, H. M. U., Aerts, J. G. J. V., Bahce, I., Niemeijer, A.-L. N., Chang, J. Y., de Groot, P. M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30391-x · Cited by 567 · see citing works

Improving immune–vascular crosstalk for cancer immunotherapy

Huang, Y., Kim, B. Y. S., Chan, C. K., Hahn, S. M., Weissman, I. L., & Jiang, W. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.145 · Cited by 563 · see citing works

Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma

Oliveira, G., Stromhaug, K., Klaeger, S., Kula, T., Frederick, D. T., Le, P. M., Forman, J., Huang, T., Li, S., Zhang, W., et al. (2021) · Nature · doi:10.1038/s41586-021-03704-y · Cited by 563 · see citing works

PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers

Yarchoan, M. M., Albacker, L. A., Hopkins, A. C., Montesion, M., Murugesan, K., Vithayathil, T., Zaidi, N., Azad, N. S., Laheru, D. A., Frampton, G. M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126908 · Cited by 554 · see citing works

T cell stemness and dysfunction in tumors are triggered by a common mechanism

Vodnala, S. K., Eil, R., Kishton, R. J., Sukumar, M., Yamamoto, T. N., Ha, N.-H., Lee, P.-H., Shin, M., Patel, S. J., Yu, Z., et al. (2019) · Science · doi:10.1126/science.aau0135 · Cited by 552 · see citing works

Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma

Hu, Z., Leet, D., Allesøe, R. L., Oliveira, G., Li, S., Luoma, A., Liu, J., Forman, J., Huang, T., Iorgulescu, J. B., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01206-4 · Cited by 550 · see citing works

Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response

Mandal, R., Samstein, R. M., Lee, K.-W., Havel, J. J., Wang, H., Krishna, C., Sabio, E. Y., Makarov, V., Kuo, F., Blecua, P., et al. (2019) · Science · doi:10.1126/science.aau0447 · Cited by 549 · see citing works

When worlds collide: Th17 and Treg cells in cancer and autoimmunity

Knochelmann, H. M., Dwyer, C. J., Bailey, S. R., Amaya, S. M., Elston, D. M., Mazza-McCrann, J. M., & Paulos, C. M. (2018) · Cellular & Molecular Immunology · doi:10.1038/s41423-018-0004-4 · Cited by 535 · see citing works

Noncoding regions are the main source of targetable tumor-specific antigens

Laumont, C. M., Vincent, K., Hesnard, L., Audemard, E. O., Bonneil, É., Laverdure, J., Gendron, P., Courcelles, M., Hardy, M., Côté, C., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5516 · Cited by 520 · see citing works

The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies

Bald, T., Krummel, M. F., Smyth, M. J., & Barry, K. C. (2020) · Nature Immunology · doi:10.1038/s41590-020-0728-z · Cited by 508 · see citing works

LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer

Tavazoie, M. F., Pollack, I., Tanqueco, R., Ostendorf, B. N., Reis, B. S., Gonsalves, F. C., Kurth, I., Andreu-Agullo, C., Derbyshire, M. L., Posada, J., et al. (2018) · Cell · doi:10.1016/j.cell.2017.12.026 · Cited by 476 · see citing works

Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel

Wang, Z., Duan, J., Cai, S., Han, M., Dong, H., Zhao, J., Zhu, B., Wang, S., Zhuo, M., Sun, J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.7098 · Cited by 471 · see citing works

CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade

Chen, L., Diao, L., Yang, Y., Yi, X., Rodriguez, B. L., Li, Y., Villalobos, P. A., Cascone, T., Liu, X., Tan, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1033 · Cited by 462 · see citing works

Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment

Zheng, Y., Chen, Z., Han, Y., Li, H., Zou, X., Zhou, B., Hu, R., Hao, J., Bai, S., Xiao, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20019-0 · Cited by 460 · see citing works

B cell-derived GABA elicits IL-10+ macrophages to limit anti-tumour immunity

Zhang, B., Vogelzang, A., Miyajima, M., Sugiura, Y., Wu, Y., Chamoto, K., Nakano, R., Hatae, R., Menzies, R. J., Sonomura, K., et al. (2021) · Nature · doi:10.1038/s41586-021-04082-1 · Cited by 455 · see citing works

NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death

Huang, D., Chen, J., Yang, L., Ouyang, Q., Li, J., Lao, L., Zhao, J., Liu, J., Lu, Y., Xing, Y., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0207-y · Cited by 445 · see citing works

Lipid signalling enforces functional specialization of Treg cells in tumours

Lim, S. A., Wei, J., Nguyen, T.-L. M., Shi, H., SU, W. W., Palacios, G. F., Dhungana, Y., Chapman, N. M., Long, L., Saravia, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03235-6 · Cited by 434 · see citing works

Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?

Strickler, J. H., Hanks, B. A., & Khasraw, M. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3054 · Cited by 418 · see citing works

Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion

Sun, X., Wu, B., Chiang, H.-C., Deng, H., Zhang, X., Xiong, W., Liu, J., Rozeboom, A. M., Harris, B. T., Blommaert, E., et al. (2021) · Nature · doi:10.1038/s41586-021-04057-2 · Cited by 407 · see citing works

Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas

Toulmonde, M., Penel, N., Adam, J., Chevreau, C., Blay, J., Cesne, A. L., Bompas, E., Piperno-Neumann, S., Cousin, S., Grellety, T., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1617 · Cited by 402 · see citing works

Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis

Mathewson, N. D., Ashenberg, O., Tirosh, I., Gritsch, S., Perez, E. M., Marx, S., Jerby‐Arnon, L., Chanoch-Myers, R., Hara, T., Richman, A. R., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.022 · Cited by 402 · see citing works

Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma

Spranger, S., Luke, J. J., Bao, R., Zha, Y., Hernandez, K. M., Yan, L., Gajewski, A. P., Andrade, J., & Gajewski, T. F. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609376113 · Cited by 399 · see citing works

Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage

Fluckiger, A., Daillère, R., Sassi, M., Sixt, B. S., Liu, P., Loos, F., Richard, C., Rabu, C., Alou, M. T., Goubet, A.-G., et al. (2020) · Science · doi:10.1126/science.aax0701 · Cited by 396 · see citing works

CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours

Zappasodi, R., Serganova, I. S., Cohen, I., Maeda, M., Shindo, M., Şenbabaoğlu, Y., Watson, M. J., Leftin, A., Maniyar, R. R., Verma, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03326-4 · Cited by 395 · see citing works

Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy

Mayoux, M., Roller, A., Pulko, V., Sammicheli, S., Chen, S., Sum, E., Jost, C., Fransen, M. F., Buser, R. B., Kowanetz, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aav7431 · Cited by 394 · see citing works

Deep learning model for the prediction of microsatellite instability in colorectal cancer: a diagnostic study

Yamashita, R., Long, J., Longacre, T., Peng, L., Berry, G., Martin, B., Higgins, J., Rubin, D. L., & Shen, J. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30535-0 · Cited by 391 · see citing works

Tumor neoantigens: from basic research to clinical applications

Jiang, T., Shi, T., Zhang, H., Hu, J., Song, Y., Wei, J., Ren, S., & Zhou, C. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0787-5 · Cited by 386 · see citing works

Stress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity

Yang, H., Xia, L., Chen, J., Zhang, S., Martin, V., Li, Q., Lin, S., Chen, J., Calmette, J., Lu, M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0566-4 · Cited by 379 · see citing works

Immunogenic neoantigens derived from gene fusions stimulate T cell responses

Yang, W., Lee, K.-W., Srivastava, R. M., Kuo, F., Krishna, C., Chowell, D., Makarov, V., Hoen, D. R., Dalin, M. G., Wexler, L. H., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0434-2 · Cited by 374 · see citing works

IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy

Zhou, T., Damsky, W., Weizman, O.-E., McGeary, M. K., Hartmann, K. P., Rosen, C. E., Fischer, S., Jackson, R. P., Flavell, R. A., Wang, J., et al. (2020) · Nature · doi:10.1038/s41586-020-2422-6 · Cited by 364 · see citing works

BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells

Seo, H., González‐Avalos, E., Zhang, W., Ramchandani, P., Yang, C., Lio, C. J., Rao, A., & Hogan, P. G. (2021) · Nature Immunology · doi:10.1038/s41590-021-00964-8 · Cited by 353 · see citing works

STAT3 Activation-Induced Fatty Acid Oxidation in CD8+ T Effector Cells Is Critical for Obesity-Promoted Breast Tumor Growth

Zhang, C.-Y., Yue, C., Herrmann, A., Song, J., Egelston, C., Wang, T., Zhang, Z.-F., Li, W.-Z., Lee, H., Aftabizadeh, M., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.10.013 · Cited by 345 · see citing works

Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non–Small Cell Lung Cancer

Kichenadasse, G., Miners, J. O., Mangoni, A. A., Rowland, A., Hopkins, A. M., & Sorich, M. J. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.5241 · Cited by 341 · see citing works

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

Rozeman, E. A., Hoefsmit, E. P., Reijers, I. L. M., Saw, R. P. M., Versluis, J. M., Krijgsman, O., Dimitriadis, P., Sikorska, K., van de Wiel, B. A., Eriksson, H., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01211-7 · Cited by 341 · see citing works

Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity

Hutton, C., Heider, F., Blanco-Gomez, A., Banyard, A., Kononov, A., Zhang, X., Karim, S., Paulus-Hock, V., Watt, D., Steele, N., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.06.017 · Cited by 337 · see citing works

β2 adrenergic receptor–mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells

Mohammadpour, H., MacDonald, C. R., Qiao, G., Chen, M., Dong, B., Hylander, B. L., McCarthy, P. L., Abrams, S. I., & Repasky, E. A. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129502 · Cited by 328 · see citing works

Cancer-cell-derived GABA promotes β-catenin-mediated tumour growth and immunosuppression

Huang, D., Wang, Y., Thompson, J. W., Yin, T., Alexander, P. B., Qin, D., Mudgal, P., Wu, H., Liang, Y., Tan, L., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-021-00820-9 · Cited by 320 · see citing works

Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer

Vernieri, C., Fucà, G., Ligorio, F., Huber, V., Vingiani, A., Iannelli, F., Raimondi, A., Rinchai, D., Frigè, G., Belfiore, A., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0030 · Cited by 319 · see citing works

Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition

Ennishi, D., Takata, K., Béguelin, W., Duns, G., Mottok, A., Farinha, P., Bashashati, A., Saberi, S., Boyle, M., Meissner, B., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1090 · Cited by 318 · see citing works

Microbiota-specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity against colorectal cancer

Overacre-Delgoffe, A. E., Bumgarner, H. J., Cillo, A. R., Burr, A. H. P., Tometich, J. T., Bhattacharjee, A., Bruno, T. C., Vignali, D. A. A., & Hand, T. W. (2021) · Immunity · doi:10.1016/j.immuni.2021.11.003 · Cited by 318 · see citing works

Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials

Dieci, M. V., Mathieu, M. C., Guarneri, V., Conte, P., Delaloge, S., André, F., & Goubar, A. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv239 · Cited by 310 · see citing works

Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages

Su, S., Zhao, J., Xing, Y., Zhang, X., Liu, J., Ouyang, Q., Chen, J., Su, F., Liu, Q., & Song, E. (2018) · Cell · doi:10.1016/j.cell.2018.09.007 · Cited by 305 · see citing works

The Mechanism of Anti–PD-L1 Antibody Efficacy against PD-L1–Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector

Dong, W., Wu, X., Ma, S., Wang, Y., Nalin, A. P., Zhu, Z. G., Zhang, J., Benson, D. M., He, K., Caligiuri, M. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1259 · Cited by 301 · see citing works

A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma Patients

Cursons, J., Souza-Fonseca-Guimarães, F., Foroutan, M., Anderson, A., Hollande, F., Hediyeh-zadeh, S., Behren, A., Huntington, N. D., & Davis, M. J. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0500 · Cited by 298 · see citing works

β-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8+ T Cells and Undermines Checkpoint Inhibitor Therapy

Bucsek, M. J., Qiao, G., MacDonald, C. R., Giridharan, T., Evans, L., Niedzwecki, B., Liu, H., Kokolus, K. M., Eng, J. W.-L., Messmer, M. N., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0546 · Cited by 294 · see citing works

Humanized Mice for the Study of Immuno-Oncology

Rochère, P. D. L., Guil‐Luna, S., Decaudin, D., Azar, G. A., Sidhu, S., & Piaggio, E. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.07.001 · Cited by 292 · see citing works

DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity

Lu, C., Guan, J., Lu, S., Jin, Q., Rousseau, B., Lu, T., Stephens, D., Zhang, H., Zhu, J., Yang, M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.006 · Cited by 285 · see citing works

Gut microbiota modulate T cell trafficking into human colorectal cancer

Cremonesi, E., Governa, V., Garzon, J. F. G., Mele, V., Amicarella, F., Muraro, M. G., Trella, E., Galati-Fournier, V., Oertli, D., Däster, S. R., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-313498 · Cited by 275 · see citing works

Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death

Hayashi, K., Nikolos, F., Lee, Y. C., Jain, A., Tsouko, E., Gao, H., Kasabyan, A., Leung, H. E., Osipov, A., Jung, S. Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19970-9 · Cited by 275 · see citing works

Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade

Gu, S. S., Zhang, W., Wang, X., Jiang, P., Traugh, N., Li, Z., Meyer, C., Stewig, B., Xie, Y., Bu, X., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0812 · Cited by 273 · see citing works

The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake

Pulido, Á. D. M., Hänggi, K., Celias, D. P., Gardner, A., Li, J., Bittencourt, B. M. B., Mohamed, E. T., Trillo-Tinoco, J., Osunmakinde, O., Peña, R. J., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.04.019 · Cited by 272 · see citing works

Turning up the heat on non-immunoreactive tumours: opportunities for clinical development

de Olza, M. O., Rodrigo, B. N., Zimmermann, S., & Coukos, G. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30234-5 · Cited by 257 · see citing works

Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti–PD-1/PD-L1 immunotherapy

Noman, M. Z., Parpal, S., Van Moer, K., Xiao, M., Yu, Y., Arakelian, T., Viklund, J., De Milito, A., Hasmim, M., Andersson, M., et al. (2020) · Science Advances · doi:10.1126/sciadv.aax7881 · Cited by 255 · see citing works

Fully automated hybrid approach to predict the IDH mutation status of gliomas via deep learning and radiomics

Choi, Y. S., Bae, S., Chang, J. H., Kang, S., Kim, S. H., Kim, J., Rim, T. H., Choi, S. H., Jain, R., & Lee, S. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa177 · Cited by 255 · see citing works

Endogenous Glucocorticoid Signaling Regulates CD8+ T Cell Differentiation and Development of Dysfunction in the Tumor Microenvironment

Acharya, N., Madi, A., Zhang, H., Klapholz, M., Escobar, G., Dulberg, S., Christian, E., Ferreira, M., Dixon, K. O., Fell, G. G., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.08.005 · Cited by 252 · see citing works

Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma

Ding, G., Ma, J., Yun, J., Chen, X., Yu, L., Zhang, S., Shi, J.-Y., Chang, Y., Ji, Y., Wang, X., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.030 · Cited by 251 · see citing works

Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response

Montesion, M., Murugesan, K., Jin, D. X., Sharaf, R., Sánchez, N., Guria, A., Minker, M., Li, G., Fisher, V. A., Sokol, E. S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0672 · Cited by 244 · see citing works

Tumor innervation: peripheral nerves take control of the tumor microenvironment

Gysler, S. M., & Drapkin, R. (2021) · Journal of Clinical Investigation · doi:10.1172/jci147276 · Cited by 227 · see citing works

Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer

Su, S., Liao, J., Liu, J., Huang, D., He, C., Chen, F., Yang, L., Wu, W., Chen, J., Lin, L., et al. (2017) · Cell Research · doi:10.1038/cr.2017.34 · Cited by 223 · see citing works

Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer

Mlecnik, B., Bifulco, C. B., Bindea, G., Marliot, F., Lugli, A., Lee, J. J., Zlobec, I., Rau, T. T., Berger, M. D., Nagtegaal, I. D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03205 · Cited by 211 · see citing works

Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade

Berry, S., Giraldo, N. A., Green, B., Cottrell, T. R., Stein, J. E., Engle, E. L., Xu, H., Ogurtsova, A., Roberts, C. A., Wang, D., et al. (2021) · Science · doi:10.1126/science.aba2609 · Cited by 195 · see citing works

Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti–PD-1 Monotherapy

Bai, X. L., Hu, J., Warner, A. B., Quach, H. T., Cann, C., Zhang, M. Z., Si, L., Tang, B., Cui, C., Yang, X., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1283 · Cited by 187 · see citing works

Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis

Lin, J. H., Huffman, A. P., Wattenberg, M. M., Walter, D. M., Carpenter, E. L., Feldser, D. M., Beatty, G. L., Furth, E. E., & Vonderheide, R. H. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20190673 · Cited by 171 · see citing works

Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity

Horton, B. L., Williams, J. B., Cabanov, A., Spranger, S., & Gajewski, T. F. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0249 · Cited by 167 · see citing works

Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance

Lin, H., Kryczek, I., Li, S., Green, M. D., Ali, A., Hamasha, R., Wei, S., Vatan, L., Szeliga, W., Grove, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.023 · Cited by 164 · see citing works

Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma

Melaiu, O., Chierici, M., Lucarini, V., Jurman, G., Conti, L. A., Vito, R. D., Boldrini, R., Cifaldi, L., Castellano, A., Furlanello, C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19781-y · Cited by 163 · see citing works

Pharmacologic Suppression of B7-H4 Glycosylation Restores Antitumor Immunity in Immune-Cold Breast Cancers

Song, X., Zhou, Z., Li, H., Xue, Y., Lu, X., Bahar, İ., Kepp, O., Hung, M., Kroemer, G., & Wan, Y. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0402 · Cited by 155 · see citing works

mRNA Delivery of a Bispecific Single‐Domain Antibody to Polarize Tumor‐Associated Macrophages and Synergize Immunotherapy against Liver Malignancies

Wang, Y., Tiruthani, K., Li, S., Hu, M., Zhong, G., Tang, Y., Roy, S., Zhang, L., Tan, J. H., Liao, C., et al. (2021) · Advanced Materials · doi:10.1002/adma.202007603 · Cited by 143 · see citing works

Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery

Chiou, S.-H., Tseng, D., Reuben, A., Mallajosyula, V., Molina, I. S., Conley, S., Wilhelmy, J., McSween, A. M., Yang, X., Nishimiya, D., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.02.014 · Cited by 133 · see citing works

Sex Hormones and Anticancer Immunity

Özdemir, B. C., & Dotto, G. P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0137 · Cited by 132 · see citing works

Secreted gelsolin inhibits DNGR-1-dependent cross-presentation and cancer immunity

Giampazolias, E., Schulz, O., Lim, K. H. J., Rogers, N. C., Chakravarty, P., Srinivasan, N., Gordon, O., Cardoso, A., Buck, M. D., Poirier, E. Z., et al. (2021) · Cell · doi:10.1016/j.cell.2021.05.021 · Cited by 132 · see citing works

Intratumoral TIGIT+ CD8+ T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer

Liu, Z., Zhou, Q., Wang, Z., Zhang, H., Zeng, H., Huang, Q., Chen, Y., Jiang, W., Lin, Z., Qu, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000978 · Cited by 125 · see citing works

Tumor-infiltrating plasmacytoid dendritic cells are associated with survival in human colon cancer

Kießler, M., Plesca, I., Sommer, U. J., Wehner, R., Wilczkowski, F., Müller, L., Tunger, A., Lai, X., Rentsch, A., Peuker, K., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001813 · Cited by 124 · see citing works

High-dimensional cytometric analysis of colorectal cancer reveals novel mediators of antitumour immunity

Vries, N. L. D., van Unen, V., Ijsselsteijn, M. E., Abdelaal, T., van der Breggen, R., Sarasqueta, A. F., Mahfouz, A. E., Peeters, K. C. M. J., Höllt, T., Lelieveldt, B. P. F., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318672 · Cited by 121 · see citing works

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma

Ng, H. H. M., Lee, R. Y., Goh, S., Tay, I. S. Y., Lim, X., Lee, B. T. K., Chew, V., Li, H., Tan, B., Lim, S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000987 · Cited by 116 · see citing works

Targeting regulator of G protein signaling 1 in tumor-specific T cells enhances their trafficking to breast cancer

Huang, D., Chen, X., Zeng, X., Lao, L., Li, J., Xing, Y., Lu, Y., Ouyang, Q., Chen, J., Yang, L., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00939-9 · Cited by 114 · see citing works

Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment

Qi, Z., Xu, Z., Zhang, L., Zou, Y., Li, J., Yan, W., Li, C., Liu, N., & Wu, H. (2022) · Nature Communications · doi:10.1038/s41467-021-27833-0 · Cited by 114 · see citing works

Turning tumors from cold to inflamed to improve immunotherapy response

Gerard, C. L., Delyon, J., Wicky, A. M., Homicskó, K., Cuendet, M. A., & Michielin, O. A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102227 · Cited by 113 · see citing works

Future prospects for CD8+ regulatory T cells in immune tolerance

Flippe, L., Bézie, S., Anegón, I., & Guillonneau, C. (2019) · Immunological Reviews · doi:10.1111/imr.12812 · Cited by 94 · see citing works

Obesity-Associated Myeloid-Derived Suppressor Cells Promote Apoptosis of Tumor-Infiltrating CD8 T Cells and Immunotherapy Resistance in Breast Cancer

Gibson, J. T., Orlandella, R. M., Turbitt, W. J., Behring, M. P., Manne, U., Sorge, R. E., & Norian, L. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.590794 · Cited by 80 · see citing works

PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy

Simon, S., Voillet, V., Vignard, V., Wu, Z., Dabrowski, C., Jouand, N., Beauvais, T., Khammari, A., Braudeau, C., Josien, R., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001631 · Cited by 77 · see citing works

Comprehensive characterization of tumor infiltrating natural killer cells and clinical significance in hepatocellular carcinoma based on gene expression profiles

Wu, M., Mei, F., Liu, W., & Jiang, J. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109637 · Cited by 65 · see citing works

The IRENA lncRNA converts chemotherapy-polarized tumor-suppressing macrophages to tumor-promoting phenotypes in breast cancer

Liu, J., Lao, L., Chen, J., Jiang, L., Zeng, W., Zhu, X., Li, J., Chen, X., Yang, L., Xing, Y., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00196-7 · Cited by 59 · see citing works

T and NK cell abundance defines two distinct subgroups of renal cell carcinoma

Lee, M. H., Järvinen, P., Nísen, H., Brück, O. E., Ilander, M., Uski, I., Theodoropoulos, J., Kankainen, M., Mirtti, T. K., Mustjoki, S. M., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2021.1993042 · Cited by 32 · see citing works

Neoadjuvant STING Activation, Extended Half-life IL2, and Checkpoint Blockade Promote Metastasis Clearance via Sustained NK-cell Activation

Milling, L. E., Garafola, D., Agarwal, Y., Wu, S., Thomas, A., Donahue, N. D., Adams, J., Thai, N., Suh, H., & Irvine, D. J. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0247 · Cited by 29 · see citing works

Cold and hot tumors: from molecular mechanisms to targeted therapy

Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 751 · see citing works

CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential

Koh, C., Lee, S., Kwak, M., Kim, B., & Chung, Y. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01105-x · Cited by 337 · see citing works

Tertiary lymphoid structures in anticancer immunity

Teillaud, J., Houel, A., Panouillot, M., Riffard, C., & Dieu‐Nosjean, M. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00728-0 · Cited by 303 · see citing works

Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides

Huang, D., Zhu, X., Ye, S., Zhang, J., Liao, J., Zhang, N., Zeng, X., Wang, J., Yang, B., Zhang, Y., et al. (2023) · Nature · doi:10.1038/s41586-023-06834-7 · Cited by 217 · see citing works

Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer

Chen, Y., Wang, D., Li, Y., Lu, Q., Si, W., Bo, Y., Chen, X., Ye, Z., Fan, H., Liu, B., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.06.009 · Cited by 215 · see citing works

Photon-Controlled Pyroptosis Activation (PhotoPyro): An Emerging Trigger for Antitumor Immune Response

Li, M., Kim, J., Rha, H., Son, S., Levine, M. S., Xu, Y., Sessler, J. L., & Kim, J. S. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c01231 · Cited by 182 · see citing works

Cancer cell-derived arginine fuels polyamine biosynthesis in tumor-associated macrophages to promote immune evasion

Zhu, Y., Zhou, Z., Du, X., Lin, X., Liang, Z.-M., Chen, S., Sun, Y., Wang, Y., Na, Z., Wu, Z., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.015 · Cited by 189 · see citing works

Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies

Zheng, S., Wang, W., Shen, L., Yao, Y., Xia, W., & Ni, C. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00543-1 · Cited by 176 · see citing works

Reactive oxygen species-powered cancer immunotherapy: Current status and challenges

He, M., Wang, M., Xu, T., Zhang, M., Dai, H., Wang, C., Ding, D., & Zhong, Z. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.02.040 · Cited by 144 · see citing works

Medicinal plant-derived mtDNA via nanovesicles induces the cGAS-STING pathway to remold tumor-associated macrophages for tumor regression

Liu, J., Xiang, J., Jin, C., Ye, L., Wang, L., Gao, Y., Lv, N., Zhang, J., You, F., Qiao, H., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01835-0 · Cited by 129 · see citing works

Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma

Sun, K., Zhang, X., Shi, J., Huang, J., Wang, S., Li, X., Lin, H., Zhao, D., Ye, M., Zhang, S., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci187024 · Cited by 130 · see citing works

Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors

Ouyang, P., Wang, L., Wu, J., Tian, Y., Chen, C., Li, D., Yao, Z., Chen, R., Xiang, G., Gong, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1344272 · Cited by 118 · see citing works

Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy

Niu, M., Yi, M., Wu, Y., Lyu, L., He, Q., Yang, R., Zeng, L., Shi, J. Y., Zhang, J., Zhou, P., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01487-5 · Cited by 106 · see citing works

Drug resistance in cancer: molecular mechanisms and emerging treatment strategies

Li, J., Hu, J., Yang, Y., Zhang, H., Liu, Y., Fang, Y., Qu, L., Lin, A., Luo, P., Jiang, A., et al. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00352-w · Cited by 101 · see citing works

Targeting DHX9 Triggers Tumor-Intrinsic Interferon Response and Replication Stress in Small Cell Lung Cancer

Murayama, T., Nakayama, J., Jiang, X., Miyata, K., Morris, A. D., Cai, K. Q., Prasad, R. M., Ma, X., Efimov, A., Belani, N., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0486 · Cited by 101 · see citing works

Enhancing immuno-oncology investigations through multidimensional decoding of tumor microenvironment with IOBR 2.0

Zeng, D., Fang, Y., Qiu, W., Luo, P., Wang, S., Shen, R., Gu, W., Huang, X., Mao, Q., Wang, G., et al. (2024) · Cell Reports Methods · doi:10.1016/j.crmeth.2024.100910 · Cited by 99 · see citing works

Tetrahedral DNA Nanostructure with Interferon Stimulatory DNA Delivers Highly Potent Toxins and Activates the cGAS‐STING Pathway for Robust Chemotherapy and Immunotherapy

Zhang, L., Wang, Y., Karges, J., Tang, D., Zhang, H., Zou, K., Song, J., & Xiao, H. (2022) · Advanced Materials · doi:10.1002/adma.202210267 · Cited by 99 · see citing works

Nanoparticle-Based Drug Delivery Systems Targeting Tumor Microenvironment for Cancer Immunotherapy Resistance: Current Advances and Applications

Wu, P., Han, J., Gong, Y., Liu, C., Yu, H., & Xie, N. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14101990 · Cited by 95 · see citing works

Polymeric nanoparticle-based nanovaccines for cancer immunotherapy

Zhang, Y., Chen, J., Shi, L., & Ma, F. (2022) · Materials Horizons · doi:10.1039/d2mh01358d · Cited by 95 · see citing works

Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial

Yin, J., Yuan, J., Li, Y., Fang, Y., Wang, R., Jiao, H., Tang, H., Zhang, S., Lin, S., Feng, S., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02469-3 · Cited by 94 · see citing works

T-cell infiltration and its regulatory mechanisms in cancers: insights at single-cell resolution

Yang, W., Liu, S., Mao, M., Gong, Y., Li, X., Lei, T., Liu, C., Wu, S., & Hu, Q. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-02960-w · Cited by 85 · see citing works

A Single‐Atom Manganese Nanozyme Mn‐N/C Promotes Anti‐Tumor Immune Response via Eliciting Type I Interferon Signaling

Qiao, W., Chen, J., Zhou, H., Hu, C., Dalangood, S., Li, H., Yang, D., Yang, Y. P., & Gui, J. (2024) · Advanced Science · doi:10.1002/advs.202305979 · Cited by 84 · see citing works

Zinc–Iron Bimetallic Peroxides Modulate the Tumor Stromal Microenvironment and Enhance Cell Immunogenicity for Enhanced Breast Cancer Immunotherapy Therapy

Lu, Y., Chen, Y., Hou, G., Lei, H., Liu, L., Huang, X., Sun, S., Liu, L., Liu, X., Na, J., et al. (2024) · ACS Nano · doi:10.1021/acsnano.3c12615 · Cited by 83 · see citing works

Cuproptosis-immunotherapy using PD-1 overexpressing T cell membrane-coated nanosheets efficiently treats tumor.

Liu, T., Zhou, Z.-H., Zhang, M.-X., Lang, P., Li, J., Liu, Z.-M., Zhang, Z., Li, L., & Zhang, L. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.08.055 · Cited by 74 · see citing works

Alendronate Triggered Dual‐Cascade Targeting Prodrug Nanoparticles for Enhanced Tumor Penetration and STING Activation of Osteosarcoma

Shen, M., Wang, Y., Bing, T., Tang, Y., Liu, X., & Yu, Y. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202307013 · Cited by 78 · see citing works

The molecular classification of cancer‐associated fibroblasts on a pan‐cancer single‐cell transcriptional atlas

Chen, B., Chan, W. N., Xie, F., Mui, C. W., Liu, X., Cheung, A. H. K., Lung, R. W. M., Chow, C., Zhang, Z., Fang, C., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1516 · Cited by 80 · see citing works

Celecoxib Augments Paclitaxel-Induced Immunogenic Cell Death in Triple-Negative Breast Cancer

Qian, X., Huang, Y., Ye, Z., Gao, B., Qian, Z., Ding, Y., Mao, Z., Du, Y., & Wang, W. (2024) · ACS Nano · doi:10.1021/acsnano.4c02947 · Cited by 78 · see citing works

Tumor microenvironment: recent advances in understanding and its role in modulating cancer therapies

Shah, D. D., Chorawala, M. R., Raghani, N. R., Patel, R., Fareed, M., Kashid, V. A., & Prajapati, B. G. (2025) · Medical Oncology · doi:10.1007/s12032-025-02641-4 · Cited by 82 · see citing works

The future of affordable cancer immunotherapy

Schaft, N., Dörrie, J., Schuler, G., Schuler‐Thurner, B., Sallam, H., Klein, S., Eisenberg, G., Frankenburg, S., Lotem, M., & Khatib, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1248867 · Cited by 78 · see citing works

Immunogenic cell death in cancer immunotherapy

Choi, M., Shin, J., Lee, C.-E., Chung, J.-Y., Kim, M., Yan, X., Yang, W., & Cha, J. (2023) · BMB Reports · doi:10.5483/bmbrep.2023-0024 · Cited by 78 · see citing works

Biomimetic Nanomodulators With Synergism of Photothermal Therapy and Vessel Normalization for Boosting Potent Anticancer Immunity

Lan, J., Zeng, R., Li, Z., Yang, X., Liu, L., Chen, L., Sun, L., Shen, Y., Zhang, T., & Ding, Y. (2024) · Advanced Materials · doi:10.1002/adma.202408511 · Cited by 75 · see citing works

Tumor cell membrane‐based vaccines: A potential boost for cancer immunotherapy

Yang, M., Zhou, J., Lu, L., Deng, D., Huang, J., Tang, Z., Shi, X., Lo, P., Lovell, J. F., Zheng, Y., et al. (2024) · Exploration · doi:10.1002/exp.20230171 · Cited by 71 · see citing works

Peptide‐Driven Proton Sponge Nano‐Assembly for Imaging and Triggering Lysosome‐Regulated Immunogenic Cancer Cell Death

He, T., Wen, J., Wang, W., Hu, Z., Ling, C., Zhao, Z., Cheng, Y., Chang, Y., Xu, M., Jin, Z., et al. (2024) · Advanced Materials · doi:10.1002/adma.202307679 · Cited by 69 · see citing works

Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside

Peyraud, F., Guégan, J., Vanhersecke, L., Brunet, M., Teyssonneau, D., Palmieri, L., Bessede, A., & Italiano, A. (2025) · Med · doi:10.1016/j.medj.2024.10.023 · Cited by 68 · see citing works

Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer

Zheng, Y., Li, S., Tang, H., Meng, X., & Zheng, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1153990 · Cited by 64 · see citing works

Tryptophan 2,3‐dioxygenase‐positive matrix fibroblasts fuel breast cancer lung metastasis via kynurenine‐mediated ferroptosis resistance of metastatic cells and T cell dysfunction

Liu, Y., Chen, S.-C., Wan, X., Wang, R., Luo, H., Chang, C., Dai, P., Gan, Y., Guo, Y., Hou, Y., et al. (2024) · 癌症：英文版 · doi:10.1002/cac2.12608 · Cited by 60 · see citing works

The role of pyroptosis and gasdermin family in tumor progression and immune microenvironment

Li, M., Jiang, P., Yang, Y., Xiong, L., Wei, S., Wang, J., & Li, C. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00464-5 · Cited by 62 · see citing works

Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion

Mitra, A., Kumar, A., Amdare, N. P., & Pathak, R. (2024) · Biology · doi:10.3390/biology13050307 · Cited by 60 · see citing works

Beyond Drug Delivery System: Immunomodulatory Layered Double Hydroxide Nanoadjuvants Take an Essential Step Forward in Cancer Immunotherapy

Zhu, C., Jiang, J., Jia, Y., Xu, Z. P., & Zhang, L. L. (2023) · Accounts of Materials Research · doi:10.1021/accountsmr.3c00094 · Cited by 53 · see citing works

Tumor-repopulating cell-derived microparticles elicit cascade amplification of chemotherapy-induced antitumor immunity to boost anti-PD-1 therapy

Bie, N., Yong, T., Wei, Z., Liang, Q., Zhang, X., Li, S., Li, X., Li, J., Gan, L., & Yang, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01658-3 · Cited by 53 · see citing works

Ablation of ERO1A induces lethal endoplasmic reticulum stress responses and immunogenic cell death to activate anti-tumor immunity

Liu, L., Li, S., Qu, Y., Bai, H., Pan, X., Wang, J., Wang, Z., Duan, J., Zhong, J., Wan, R., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101206 · Cited by 52 · see citing works

Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies

Vryza, P., Fischer, T., Mistakidi, E., & Zaravinos, A. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101788 · Cited by 54 · see citing works

Single-cell omics traces the heterogeneity of prostate cancer cells and the tumor microenvironment

Yu, X., Liu, R., Gao, W., Wang, X., & Zhang, Y. (2023) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-023-00450-z · Cited by 52 · see citing works

Inhibition of CDC20 potentiates anti-tumor immunity through facilitating GSDME-mediated pyroptosis in prostate cancer

Wu, F., Wang, M., Zhong, T., Xiao, C., Chen, X., Huang, Y., Wu, M., Yu, J., & Chen, D. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00428-9 · Cited by 48 · see citing works

Integrated bulk and single-cell transcriptomes reveal pyroptotic signature in prognosis and therapeutic options of hepatocellular carcinoma by combining deep learning

Liu, Y., Li, H., Zeng, T., Wang, Y., Zhang, H., Wan, Y., Shi, Z., Cao, R., & Tang, H. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad487 · Cited by 48 · see citing works

Intratumoral CD103 + CD8 + T cells predict response to neoadjuvant chemoimmunotherapy in advanced head and neck squamous cell carcinoma

Ren, S., Lan, T., Wu, F., Chen, S., Jiang, X., Huo, C., Li, Z., Xie, S., Wu, D., Wang, R., et al. (2023) · 癌症：英文版 · doi:10.1002/cac2.12480 · Cited by 45 · see citing works

Free Radicals Generated in Perfluorocarbon–Water (Liquid–Liquid) Interfacial Contact Electrification and Their Application in Cancer Therapy

Li, H., Wang, Z., Chu, X., Zhao, Y., He, G., Hu, Y., Liu, Y., Wang, Z. L., & Jiang, P. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c02149 · Cited by 45 · see citing works

Immunotherapy in breast cancer: current landscape and emerging trends

Ran, R., Chen, X., Yang, J., & Xu, B. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00667-y · Cited by 45 · see citing works

Gut Microbiota and Tumor Immune Escape: A New Perspective for Improving Tumor Immunotherapy

He, Y., Huang, J., Li, Q., Xia, W., Zhang, C., Liu, Z., Xiao, J., Yi, Z., Deng, H., Xiao, Z., et al. (2022) · Cancers · doi:10.3390/cancers14215317 · Cited by 45 · see citing works

TAM-targeted reeducation for enhanced cancer immunotherapy: Mechanism and recent progress

Shen, X., Zhou, S., Yang, Y., Tu, H., Xiang, Z., Zhao, J., Zhu, C., Zeng, L., & Zhang, L. L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1034842 · Cited by 44 · see citing works

Integration of STING activation and COX-2 inhibition via steric-hindrance effect tuned nanoreactors for cancer chemoimmunotherapy

Zhang, P., Zhong, D., Yu, Y., Wang, L., Li, Y., Liang, Y., Shi, Y., Duan, M., Li, B., Niu, H., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122695 · Cited by 44 · see citing works

CCR8: a promising therapeutic target against tumor-infiltrating regulatory T cells

Wen, Y., Xia, Y., Yang, X., Li, H., & Gao, Q. (2025) · Trends in Immunology · doi:10.1016/j.it.2025.01.001 · Cited by 44 · see citing works

Engineered NanoAlum from aluminum turns cold tumor hot for potentiating cancer metalloimmunotherapy

Jia, Y., Hu, J., Zhu, C., Li, Z., Yang, X., Liu, R., Zeng, L., & Zhang, L. L. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.043 · Cited by 46 · see citing works

The enrichment of the gut microbiota Lachnoclostridium is associated with the presence of intratumoral tertiary lymphoid structures in hepatocellular carcinoma

Zhao, R., Li, J., Chen, B., Zhao, J., Hu, L., Huang, K., Chen, Q., Yao, J., Lin, G., Bao, L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1289753 · Cited by 43 · see citing works

Radiomics signature for dynamic monitoring of tumor inflamed microenvironment and immunotherapy response prediction

Bernatowicz, K., Amat, R., Prior, O., Frigola, J., Ligero, M., Grussu, F., Zatse, C., Serna, G., Nuciforo, P. G., Toledo, R. A., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009140 · Cited by 43 · see citing works

Atypical chemokine receptors: emerging therapeutic targets in cancer

Torphy, R. J., Yee, E. J., Schulick, R. D., & Zhu, Y. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.09.009 · Cited by 43 · see citing works

T cell exhaustion in human cancers

Kang, K., Lin, X., Chen, P., Liu, H., Liu, F., Xiong, W., Li, G., Yi, M., Li, X., Wang, H., et al. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189162 · Cited by 45 · see citing works

Engineering metal‐phenolic networks for enhancing cancer therapy by tumor microenvironment modulation

Xie, L., Li, J., Wang, L., & Dai, Y. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1864 · Cited by 41 · see citing works

Comprehensive characterization of tumor microenvironment in colorectal cancer via molecular analysis

Wu, X., Yan, H., Qiu, M., Qu, X., Wang, J., Xu, S., Zheng, Y., Ge, M., Yan, L., & Li, L. (2023) · eLife · doi:10.7554/elife.86032 · Cited by 42 · see citing works

Combination of IDO inhibitors and platinum(IV) prodrugs reverses low immune responses to enhance cancer chemotherapy and immunotherapy for osteosarcoma

Xiang, D., Han, X.-L., Li, J., Zhang, J., Xiao, H., Li, T., Zhao, X., Xiong, H., Xu, M., & Bi, W. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100675 · Cited by 39 · see citing works

Intimate communications within the tumor microenvironment: stromal factors function as an orchestra

Cheng, B., Yu, Q., & Wang, W. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-022-00894-z · Cited by 41 · see citing works

Low-intensity focused ultrasound targeted microbubble destruction reduces tumor blood supply and sensitizes anti-PD-L1 immunotherapy

Wu, N., Cao, Y., Liu, Y., Zhou, Y., He, H., Tang, R., Wan, L., Wang, C., Xiong, X., Zhong, L., et al. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1173381 · Cited by 37 · see citing works

Supplementation with a high-glucose drink stimulates anti-tumor immune responses to glioblastoma via gut microbiota modulation

Kim, J.-H., Kim, Y., La, J., Park, W. H., Kim, H.-J., Park, S. H., Ku, K. B., Kang, B. H., Lim, J., Kwon, M. S., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113220 · Cited by 38 · see citing works

Reciprocal inhibition between TP63 and STAT1 regulates anti-tumor immune response through interferon-γ signaling in squamous cancer

Jiang, Y., Zheng, Y., Zhang, Y., Kong, S., Dong, J., Wang, F., Ziman, B., Gery, S., Hao, J., Zhou, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46785-9 · Cited by 37 · see citing works

First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial

Tian, X., Cai, J., Xia, Y., Zhang, Y., Wang, L., Liu, P., Huang, H., Li, Y., Zhou, H., Li, Z., et al. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00066-8 · Cited by 37 · see citing works

Bacteria-driven nanosonosensitizer delivery system for enhanced breast cancer treatment through sonodynamic therapy-induced immunogenic cell death

Du, M., Wang, T., Peng, W., Feng, R., Goh, M., & Chen, Z. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02437-0 · Cited by 36 · see citing works

Stromal Stiffness-Regulated IGF2BP2 in Pancreatic Cancer Drives Immune Evasion via Sphingomyelin Metabolism

Tang, R., Zhang, Z., Liu, X., Liao, Y., Chen, Y., Xiao, M., Li, Y., Zhou, C., Tan, Z., Zhang, C., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.03.019 · Cited by 36 · see citing works

Radiotherapy, Chemotherapy and Immunotherapy—Current Practice and Future Perspectives for Recurrent/Metastatic Oral Cavity Squamous Cell Carcinoma

Melo-Alvim, C., Neves, M. E., Santos, J. L., Abrunhosa-Branquinho, A. N., Barroso, T., Costa, L., & Ribeiro, L. (2022) · Diagnostics · doi:10.3390/diagnostics13010099 · Cited by 35 · see citing works

Infiltration characteristics and regulatory mechanisms of CD8+ T lymphocytes in solid tumors: spatial distribution, biological functions, and interactions with the immune microenvironment

Ouyang, P., Zhang, J., He, X., Yang, C., Zeng, D., & Xu, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1661545 · Cited by 36 · see citing works

Systemic Delivery of mPEG‐Masked Trispecific T‐Cell Nanoengagers in Synergy with STING Agonists Overcomes Immunotherapy Resistance in TNBC and Generates a Vaccination Effect

Shen, M., Chen, C., Guo, Q., Wang, Q., Liao, J., Wang, L., Yu, J. Y., Xue, M., Duan, Y., & Zhang, J. (2022) · Advanced Science · doi:10.1002/advs.202203523 · Cited by 34 · see citing works

Engineered IL-7 synergizes with IL-12 immunotherapy to prevent T cell exhaustion and promote memory without exacerbating toxicity

Kang, S., Mansurov, A., Kurtanich, T. R., Chun, H. R., Slezak, A. J., Volpatti, L. R., Chang, K., Wang, T., Alpar, A. T., Refvik, K. C., et al. (2023) · Science Advances · doi:10.1126/sciadv.adh9879 · Cited by 33 · see citing works

Nanomaterials: leading immunogenic cell death-based cancer therapies

Ma, C., Cheng, Z., Tan, H., Wang, Y., Sun, S., Zhang, M., & Wang, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1447817 · Cited by 33 · see citing works

T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors

Middelburg, J., Sluijter, M., Schaap, G., Göynük, B., Lloyd, K. A., Ovcinnikovs, V., Zom, G. G., Marijnissen, R. J., Groeneveldt, C., Griffioen, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44308-6 · Cited by 32 · see citing works

Unraveling the role of M1 macrophage and CXCL9 in predicting immune checkpoint inhibitor efficacy through multicohort analysis and single‐cell RNA sequencing

Yu, Y., Chen, H., Ouyang, W., Zeng, J., Huang, H., Mao, L., Jia, X., Guan, T., Wang, Z., Lin, R., et al. (2024) · MedComm · doi:10.1002/mco2.471 · Cited by 32 · see citing works

Engineering CRISPR System‐Based Bacterial Outer Membrane Vesicle Potentiates T Cell Immunity for Enhanced Cancer Immunotherapy

Wang, H., Zhan, H., Pan, B., Zeng, L., Chen, Z., Liu, S., Zhang, Q., Hong, X., Lu, J., Lin, X., et al. (2025) · Advanced Materials · doi:10.1002/adma.202501565 · Cited by 33 · see citing works

Combining precision oncology and immunotherapy by targeting the MALT1 protease

Mempel, T. R., & Krappmann, D. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005442 · Cited by 31 · see citing works

Tumor-targeting hydroxyapatite nanoparticles for remodeling tumor immune microenvironment (TIME) by activating mitoDNA-pyroptosis pathway in cancer

Yang, Y., Yang, J., Zhu, N., Qiu, H., Feng, W., Chen, Y., Chen, X., Chen, Y., Zheng, W., Liang, M., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02231-4 · Cited by 31 · see citing works

Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials

Yu, J., Li, M., Ren, B., Cheng, L., Wang, X., Ma, Z., Yong, W. P., Chen, X., Wang, L., & Goh, B. C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1261575 · Cited by 29 · see citing works

Tumor microenvironment-reprogrammable CpG-templated copper sulfide loaded with disulfiram for sensitized cuproptosis immunotherapy

Zhao, P., Wang, H., Zhao, H., Yin, C., Xing, Y., Wang, J., Chi, L., Ye, L., & Gu, W. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.150524 · Cited by 28 · see citing works

The circRNA cEMSY Induces Immunogenic Cell Death and Boosts Immunotherapy Efficacy in Lung Adenocarcinoma

Zhang, Y., Song, X., Feng, Y., Qian, Y., Chen, B., Zhang, T., Wang, H., Chen, Y., Yu, X., Ding, H., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-1484 · Cited by 32 · see citing works

Identification and Analysis of Immune-Related Gene Signature in Hepatocellular Carcinoma

Shen, B., Zhang, G., Liu, Y., Wang, J., & Jiang, J. (2022) · Genes · doi:10.3390/genes13101834 · Cited by 28 · see citing works

Carboxymethylated Alginate-Resiquimod Micelles Reverse the Immunosuppressive Tumor Microenvironment and Synergistically Enhance the Chemotherapy and Immunotherapy for Gastric Cancer

Chen, J., Liu, X., Zhao, S., Chen, H., Lu, T., Wang, J., Han, J., Wu, W., Shen, X., & Li, C. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c06828 · Cited by 28 · see citing works

Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8 + T cell infiltration and functional transition

Yu, A., Hu, J., Fu, L., Huang, G., Deng, D., Zhang, M., Wang, Y., Shu, G., Jing, L., Li, H., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007230 · Cited by 28 · see citing works

Synergizing CXCL9 with BRD4‐PROTAC Using Nanochaperone Boosts Robust T Cell‐Dependent Antitumor Immune Responses for Cancer Immunotherapy

Chen, J., Ma, F., Zhang, Y., Xu, M., Xu, L., Liu, Y., Ma, R., & Shi, L. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202314203 · Cited by 27 · see citing works

B7-H3 in Cancer Immunotherapy—Prospects and Challenges: A Review of the Literature

Mielcarska, S., Kot, A., Dawidowicz, M., Kula, A., Sobków, P., Kłaczka, D., Waniczek, D., & Świętochowska, E. (2025) · Cells · doi:10.3390/cells14151209 · Cited by 28 · see citing works

Focused acoustic vortex-mediated sonochemotherapy for the amplification of immunogenic cell death combined with checkpoint blockade to potentiate cancer immunotherapy

Ya, Z., Guo, S., Li, Y., Zhu, M., Zhang, L., Zong, Y., & Wan, M. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122278 · Cited by 27 · see citing works

Light‐Enhanced Hypoxia‐Responsive Gene Editing for Hypoxia‐Resistant Photodynamic and Immunotherapy

Qu, S., Ji, Y., Fan, L., Yan, T., Zhu, G., Song, H., Yang, K., & Han, X. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202302615 · Cited by 26 · see citing works

The cellular composition of the tumor microenvironment is an important marker for predicting therapeutic efficacy in breast cancer

Dou, T., Li, J., Zhang, Y., Pei, W., Zhang, B., Wang, B., Wang, Y., & Jia, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1368687 · Cited by 27 · see citing works

Neoadjuvant chemoimmunotherapy in resectable locally advanced oral squamous cell carcinoma: a single-center retrospective cohort study

Li, B., Xie, S., Han, J., Cao, H., Lin, Z., Hu, H., Pan, C., Li, Q., Li, J., Wang, L., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001891 · Cited by 27 · see citing works

Extracellular vesicles in cancer drug resistance: Mechanistic insights and therapeutic implications

Zuo, J., Yan, H., Qin, S., Yan, Y., Wang, S., Yang, L., Yang, J., & Yang, J. H. (2024) · MedComm – Oncology · doi:10.1002/mog2.94 · Cited by 26 · see citing works

Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario

Spagnolo, C. C., Giuffrida, G., Cannavò, S., Franchina, T., Silvestris, N., Ruggeri, R. M., & Santarpía, M. (2022) · Cancers · doi:10.3390/cancers15010246 · Cited by 28 · see citing works

Targeting ENPP1 for cancer immunotherapy: Killing two birds with one stone

Huang, R., Ning, Q., Zhao, J., Zhao, X., Zeng, L., Yi, Y., & Tang, S. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.116006 · Cited by 25 · see citing works

NIR-715 photodynamic therapy induces immunogenic cancer cell death by enhancing the endoplasmic reticulum stress response

Zheng, Z.-Y., Lin, W., Su, J.-W., Huang, Q., Zhang, C., Pan, W.-X., Li, E., Zhang, H., & Xu, L. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07283-4 · Cited by 25 · see citing works

Tumor Immunophenotyping‐Derived Signature Identifies Prognosis and Neoadjuvant Immunotherapeutic Responsiveness in Gastric Cancer

Wang, J., Qiu, Q., Zheng, Q., Zhao, Y., Xu, Y., Zhang, T., Wang, S., Wang, Q., Jin, Q., Ye, Y., et al. (2023) · Advanced Science · doi:10.1002/advs.202207417 · Cited by 24 · see citing works

Polyamine metabolism and anti-tumor immunity

Wu, J., Zeng, Y. J., You, Y.-Y., & Chen, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1529337 · Cited by 25 · see citing works

Understanding and Overcoming Immunosuppression Shaped by Cancer Stem Cells

Li, L., & Jensen, R. A. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0230 · Cited by 24 · see citing works

Targeting Alpha‐Ketoglutarate Disruption Overcomes Immunoevasion and Improves PD‐1 Blockade Immunotherapy in Renal Cell Carcinoma

Li, L., Zeng, X., Chao, Z., Luo, J., Guan, W., Zhang, Q., Ge, Y., Wang, Y., Xiong, Z., Ma, S., et al. (2023) · Advanced Science · doi:10.1002/advs.202301975 · Cited by 23 · see citing works

Immunological modifications following chemotherapy are associated with delayed recurrence of ovarian cancer

Adzibolosu, N. K., Alvero, A. B., Ali‐Fehmi, R., Gogoi, R. P., Corey, L., Tedja, R., Chehade, H., Gogoi, V., Morris, R. T., Anderson, M. L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1204148 · Cited by 23 · see citing works

Nanotechnology‐Empowered Combination Cancer Immunotherapies: Mechanisms, Synergies, and Perspectives

Pan, Y., Xue, X., & Liang, X. (2024) · Advanced NanoBiomed Research · doi:10.1002/anbr.202300129 · Cited by 23 · see citing works

A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune

Jiang, Z., Cai, G., Liu, H., Liu, L., Huang, R., Nie, X.-M., Gui, R., Li, J., Ma, J., Cao, K., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02525-1 · Cited by 23 · see citing works

Cold and hot tumors: from molecular mechanisms to targeted therapy

Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 751 · see citing works

Immunologic tumor microenvironment modulators for turning cold tumors hot

Khosravi, G. R., Mostafavi, S., Bastan, S., Ebrahimi, N., Gharibvand, R. S., & Eskandari, N. (2024) · 癌症：英文版 · doi:10.1002/cac2.12539 · Cited by 384 · see citing works

Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors

Ouyang, P., Wang, L., Wu, J., Tian, Y., Chen, C., Li, D., Yao, Z., Chen, R., Xiang, G., Gong, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1344272 · Cited by 118 · see citing works

Turning cold tumors into hot tumors to ignite immunotherapy

Liu, Y., Wang, Y., Wang, S., Li, J., He, W. A., Fan, X.-J., & Wan, X. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02477-6 · Cited by 104 · see citing works

Igniting Hope for Tumor Immunotherapy: Promoting the “Hot and Cold” Tumor Transition

Chen, W., Ma, Y., Wang, F., Liao, Y., Chen, Y., Zhao, B., Zhao, Q., Wang, D., & Tang, D. (2022) · Clinical Medicine Insights Oncology · doi:10.1177/11795549221120708 · Cited by 28 · see citing works